Related references
Note: Only part of the references are listed.Tivantinib added to erlotinib in nonsmall-cell lung cancer: the primary end point was not MET ...
G. V. Scagliotti et al.
ANNALS OF ONCOLOGY (2015)
Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer
V. Dieras et al.
ANNALS OF ONCOLOGY (2015)
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
H. Yoshioka et al.
ANNALS OF ONCOLOGY (2015)
The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Martijn P. Lolkema et al.
CLINICAL CANCER RESEARCH (2015)
Cellular and molecular mechanisms of HGF/Met in the cardiovascular system
Simona Gallo et al.
CLINICAL SCIENCE (2015)
Designing chimeric antigen receptors to effectively and safely target tumors
Michael C. Jensen et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Hepatocyte Growth Factor Receptor c-Met Instructs T Cell Cardiotropism and Promotes T Cell Migration to the Heart via Autocrine Chemokine Release
Izabela Komarowska et al.
IMMUNITY (2015)
Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors
Hinrich Abken
IMMUNOTHERAPY (2015)
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
Sara M. Tolaney et al.
INVESTIGATIONAL NEW DRUGS (2015)
Phase I study of ABT-700, an anti-c-Met antibody, in patients (pts) with advanced gastric or esophageal cancer (GEC).
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Predictive Value of Positron Emission Tomography/Computed Tomography to Assess Early Treatment Response to Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade Without Chemotherapy for HER2-Positive Metastatic Breast Cancer: Are We Ready to Embrace This Early Metabolic Look Strategy?
Komal Jhaveri et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Defining a Role and Predicting Benefit From Platinum-Based Therapy in Breast Cancer: An Evolving Story
Joseph A. Sparano
JOURNAL OF CLINICAL ONCOLOGY (2015)
Reply to WAA Tjalma and JS Grossman
Bradley J. Monk et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized phase II study of FOLFOX plus /- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC)
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
c-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma
Lan Zhao et al.
JOURNAL OF PATHOLOGY (2015)
MET is required for the recruitment of anti-tumoural neutrophils
Veronica Finisguerra et al.
NATURE (2015)
Neutrophils support lung colonization of metastasis-initiating breast cancer cells
Stefanie K. Wculek et al.
NATURE (2015)
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Seth B. Coffelt et al.
NATURE (2015)
Adoptive Cell Therapy-Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors
Steven A. Feldman et al.
SEMINARS IN ONCOLOGY (2015)
A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
David S. Hong et al.
ONCOTARGET (2015)
Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer
Jitka Y. Sagiv et al.
CELL REPORTS (2015)
c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma
Takumi Kumai et al.
ONCOIMMUNOLOGY (2015)
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
S. Pant et al.
ANNALS OF ONCOLOGY (2014)
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
A. Patnaik et al.
BRITISH JOURNAL OF CANCER (2014)
Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
Hartmut Koeppen et al.
CLINICAL CANCER RESEARCH (2014)
A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
Josep Tabernero et al.
CLINICAL CANCER RESEARCH (2014)
Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Ravi Salgia et al.
CLINICAL CANCER RESEARCH (2014)
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
Yoon-Koo Kang et al.
INVESTIGATIONAL NEW DRUGS (2014)
Effect of Onartuzumab Added to Erlotinib on Metastasis in Patients With Lung Cancer Reply
David Robert Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Hepatocyte growth factor in dampening liver immune-mediated pathology in acute viral hepatitis without compromising antiviral activity
Renan Aguilar-Valenzuela et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2
Pei-Min Chen et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2014)
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson et al.
LANCET ONCOLOGY (2014)
MET inhibitors start on road to recovery
Ken Garber
NATURE REVIEWS DRUG DISCOVERY (2014)
c-Met-Dependent Multipotent Labyrinth Trophoblast Progenitors Establish Placental Exchange Interface
Masaya Ueno et al.
DEVELOPMENTAL CELL (2013)
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
Darren R. Feldman et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Imaging haematopoietic cells recruitment to an acute wound in vivo identifies a role for c-Met signalling
K. Falenta et al.
JOURNAL OF MICROSCOPY (2013)
The neurotrophic hepatocyte growth factor attenuates CD8+ cytotoxic T-lymphocyte activity
Mahdia Benkhoucha et al.
JOURNAL OF NEUROINFLAMMATION (2013)
Transforming growth factor-β1 selectively inhibits hepatocyte growth factor expression via a micro-RNA-199-dependent posttranscriptional mechanism
Ognoon Mungunsukh et al.
MOLECULAR BIOLOGY OF THE CELL (2013)
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro et al.
LANCET ONCOLOGY (2013)
A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity
R. Castoldi et al.
ONCOGENE (2013)
Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Simona Corso et al.
CANCER DISCOVERY (2013)
Multipotent Human Mesenchymal Stromal Cells Mediate Expansion of Myeloid-Derived Suppressor Cells via Hepatocyte Growth Factor/c-Met and STAT3
B. Linju Yen et al.
STEM CELL REPORTS (2013)
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
Jonathan W. Goldman et al.
CANCER (2012)
MiR-1 Downregulation Cooperates with MACC1 in Promoting MET Overexpression in Human Colon Cancer
Cristina Migliore et al.
CLINICAL CANCER RESEARCH (2012)
The HGF Receptor/Met Tyrosine Kinase Is a Key Regulator of Dendritic Cell Migration in Skin Immunity
Jea-Hyun Baek et al.
JOURNAL OF IMMUNOLOGY (2012)
MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
Chin-Tung Chen et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Alex Kentsis et al.
NATURE MEDICINE (2012)
MET: a promising anticancer therapeutic target
Solange Peters et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Barbara Sennino et al.
CANCER DISCOVERY (2012)
Enhanced c-Met activity promotes G-CSF-induced mobilization of hematopoietic progenitor cells via ROS signaling
Melania Tesio et al.
BLOOD (2011)
Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung
Zvi Granot et al.
CANCER CELL (2011)
The Evolving War on Cancer
Daniel A. Haber et al.
CELL (2011)
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
Lee S. Rosen et al.
CLINICAL CANCER RESEARCH (2011)
Hyaluronan-CD44 interactions as potential targets for cancer therapy
Suniti Misra et al.
FEBS JOURNAL (2011)
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
Jochen K. Lennerz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Wild-type p53 controls cell motility and invasion by dual regulation of MET expression
Chang-Il Hwang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
MET signalling: principles and functions in development, organ regeneration and cancer
Livio Trusolino et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Hepatocyte Growth Factor Modulates Interleukin-6 Production in Bone Marrow Derived Macrophages: Implications for Inflammatory Mediated Diseases
Gina M. Coudriet et al.
PLOS ONE (2010)
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells
Mahdia Benkhoucha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN
Zvi G. Fridlender et al.
CANCER CELL (2009)
Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer
Jihong Ma et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis
Ulrike Stein et al.
NATURE MEDICINE (2009)
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
Seiji Yano et al.
CANCER RESEARCH (2008)
NK4 gene therapy targeting HGF-MET and angiogenesis
Kunio Matsumoto et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
被撤回的出版物: Down-regulation of Micro-RNA-1 (miR-1) in Lung Cancer SUPPRESSION OF TUMORIGENIC PROPERTY OF LUNG CANCER CELLS AND THEIR SENSITIZATION TO DOXORUBICIN-INDUCED APOPTOSIS BY miR-1 (Retracted article. See vol. 293, pg. 12945, 2018)
Mohd W. Nasser et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Silencing the MET oncogene leads to regression of experimental tumors and metastases
S. Corso et al.
ONCOGENE (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Hepatocyte growth factor significantly suppresses collagen-induced arthritis in mice
Katsuhide Okunishi et al.
JOURNAL OF IMMUNOLOGY (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development
Y. Liu et al.
JOURNAL OF PATHOLOGY (2007)
c-Met is essential for wound healing in the skin
Jolanta Chmielowiec et al.
JOURNAL OF CELL BIOLOGY (2007)
Tolerogenic dendritic cells: cytokine modulation comes of age
Sergio Rutella et al.
BLOOD (2006)
Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment
Hanako Kobayashi et al.
BLOOD (2006)
Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: Targeting the inflamed vascular endothelium
Rujun Gong et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
A novel role of hepatocyte growth regulator through suppressing factor as an immune dendritic cell function
K Okunishi et al.
JOURNAL OF IMMUNOLOGY (2005)
Mechanisms and significance of bifunctional NK4 in cancer treatment
K Matsumoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Hepatocyte growth factor ameliorates the progression of experimental autoimmune myocarditis - A potential role for induction of T helper 2 cytokines
H Futamatsu et al.
CIRCULATION RESEARCH (2005)
Ameliorating effect of hepatocyte growth factor on inflammatory bowel disease in a murine model
K Oh et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2005)
Hepatocyte growth factor attenuates airway hyperresponsiveness, inflammation, and remodeling
W Ito et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2005)
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair
CG Huh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation - Induction of tolerance and prevention of cardiac allograft vasculopathy
K Yamaura et al.
CIRCULATION (2004)
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
P Michieli et al.
CANCER CELL (2004)
Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action
YH Liu
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2004)
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation
YW Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The Semaphorin 4D receptor controls invasive growth by coupling with Met
S Giordano et al.
NATURE CELL BIOLOGY (2002)
Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli
M Di Nicola et al.
BLOOD (2002)
A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth
L Trusolino et al.
CELL (2001)
A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats
H Ueda et al.
CARDIOVASCULAR RESEARCH (2001)
Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases
K Matsumoto et al.
KIDNEY INTERNATIONAL (2001)
Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function
T Kuroiwa et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
The role of hepatocyte growth factor and its receptor c-met in interactions between lymphocytes and stromal cells in secondary human lymphoid organs
G Skibinski et al.
IMMUNOLOGY (2001)
Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma
R Abounader et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Hepatocyte growth factor is a regulator of monocyte-macrophage function
F Galimi et al.
JOURNAL OF IMMUNOLOGY (2001)
Overexpression and regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma
XP Zhu et al.
UROLOGY (2000)
Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF
T Nakamura et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Mechanism of regulation of HGF/SF gene expression in fibroblasts by TGF-β1
P Harrison et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Share Paper
